ROCKVILLE, Md. — Catalyst Rx, the pharmacy benefit management (PBM) subsidiary of
Catalyst Health Solutions, Inc. (NASDAQ: CHSI), announced the award of a
new service contract with the State of Louisiana Office of Group
Benefits (OGB) following the State’s competitive bid process. The new
contract, effective July 1, 2010, covers approximately 225,000 members.
Catalyst Rx first began administering pharmacy benefits for OGB on July
1, 2004. “Catalyst Rx appreciates the opportunity to extend our
relationship with OGB and manage pharmacy benefits for the State of
Louisiana’s active and retired employees and their dependents,” said
David T. Blair, Chief Executive Officer of Catalyst Health Solutions.
“We remain firmly committed to building on our collaborative partnership
and driving the most care-effective, cost-effective solutions for the
State.” In 2008, Catalyst Rx and the OGB were the recipients of a
Pharmacy Benefit Management Institute (PBMI) Rx Benefit Innovation Award
for their physician outreach program that significantly increased the
prescribing and utilization of generic drugs, resulting in a three-year
savings of $28 million for the OGB.
Catalyst Health Solutions, Inc. is built on strong, innovative
principles in the management of prescription drug benefits and provides
an unbiased, client-centered philosophy resulting in industry-leading
client retention rates. The Companys subsidiaries include Catalyst Rx,
a full-service pharmacy benefit manager serving more than 6 million
lives in the United States and Puerto Rico; HospiScript Services, LLC,
one of the largest providers of pharmacy benefit management services to
the hospice industry; and Immediate Pharmaceutical Services, Inc., a
fully-integrated prescription mail service facility in Avon Lake, Ohio.
The Companys clients include self-insured employers including state and
local governments, managed care organizations, unions, hospices,
third-party administrators and individuals.
This press release may contain “forward-looking statements” as defined
in the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties that might
materially affect our results, particularly those risks referred to in
our Annual Report on Form 10-K for the year ended December 31, 2008
under “Item 1A. Risk Factors.” Readers are urged to carefully review and
consider the various disclosures made in our Annual Report on Form 10-K
and our other filings with the Securities and Exchange Commission that
attempt to advise interested parties of the risks and uncertainties that
may affect our business. Catalyst Health Solutions, Inc. does not
undertake any obligation to update forward-looking statements, whether
as a result of new information, future events, or other developments.
CONCEPCION, Chile — Chile launched a hepatitis and tetanus vaccination campaign Friday and doctors warned of outbreaks of diarrhea and infection among thousands of people displaced by the earthquake and the tsunami that heavily damaged or destroyed 36 hospitals and made garbage dumps of coastal towns and cities. With many pharmacies looted, people suffering from diabetes, hypertension and psychological illnesses are going without medicine. “We are going to keep needing water, electric systems, a functioning sewage system. We need to clean up rotting fish in the streets. We need chemical toilets, and when it starts raining, people living in tents are going to get wet and sick. All this is going to cause infections,” said Talcahuano Mayor Gaston Saavedra, whose port city was heavily damaged by the Feb. 27 quake and tsunami. Chile said more than a dozen of its own military and civilian field hospitals were operating Friday. Mobile hospitals from a half- dozen other countries also were opening or about to open — an unusual situation for a country that proudly sends rescue and relief teams to the worlds trouble spots.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL),
a specialty biopharmaceutical company, today announced that XIAFLEX
(collagenase clostridium histolyticum), a novel,
first-in-class,
orphan-designated, biologic, is now available by prescription in the United
States for the treatment of adult Dupuytrens contracture patients with a
palpable cord.
The Company has established a distribution network that will allow health
care providers to access XIAFLEX in an office setting through specialty
distributors and specialty pharmacies or, in the institutional setting,
through selected wholesalers. Physicians can receive XIAFLEX after they
have undergone training on XIAFLEX, and enrolled themselves and their site
of care in the distribution network.
“XIAFLEX is the first and only FDA-approved nonsurgical treatment for
Dupuytrens contracture and we believe it could represent a major
breakthrough for patients suffering from the debilitating effects of
Dupuytrens contracture,” said Armando Anido, Chief Executive Officer and
President of Auxilium. “I am extremely proud of the XIAFLEX team, whose
commitment and hard work have allowed us to give patients access to XIAFLEX
just five weeks following FDA approval. We are committed to making XIAFLEX
broadly available to appropriate Dupuytrens patients and have implemented
patient and healthcare professional assistance programs to support the
launch of XIAFLEX.”